期刊文献+

富马酸替诺福韦二吡呋酯的合成 被引量:1

Synthesis of Tenofovir disoproxil fumarate
下载PDF
导出
摘要 实验以(R)-(+)-9-(2-羟丙基)腺嘌呤为起始原料,经膦酸酯缩合反应、水解反应、取代反应、成盐反应及重结晶提纯5个步骤而得到富马酸替诺福韦二吡呋酯成品,总收率51.0%。目标产物结构经^(1)H NMR、^(13)C NMR、HI-MS表征。该工艺路线用到的试剂常见,各步反应条件温和,后处理操作简易,适合工业化生产。 Tenofovir disoproxil fumarate was prepared via phosphonate condensation,hydrolysis,substitution,salt formation and recrystallization reaction using(R)-(+)-9-(2-hydroxypropyl)adenine as raw material.The total yield of the product can be up to 51.0%.The structures of the target compound were confirmed by^(1)H NMR,^(13)C NMR and HI-MS.The reagents used in this technical process route are common,the reaction conditions of each step are mild,the post-treatment operation is simple,so it is suitable for industrial production.
作者 朱卫兵 ZHU Wei-bing(Anhui Ankehengyi Pharmaceutical Co.,Ltd.,Tongling 244000,China)
出处 《应用化工》 CAS CSCD 北大核心 2020年第S02期360-362,共3页 Applied Chemical Industry
关键词 富马酸替诺福韦二吡呋酯 (R)-(+)-9-(2-羟丙基)腺嘌呤 富马酸 Tenofovir disoproxil fumarate (R)-(+)-9-(2-hydroxypropyl)adenine Fumaric acid
  • 相关文献

参考文献3

二级参考文献21

  • 1Schultze LM, Chapman HH, Dubree NJP,et al, Practical synthesis of the anti-HIV drug, PMPA[J]. Tetrahedron Lett, 1998,39 (14) :1 853 -1 856.
  • 2Munger JD,Rohloff JC,Schultze LM. Nucleotide analog composition and synthesis method : W0,99/05150 [ P ].1999-02-04.
  • 3Bisehofberger NW. PMPA preparation : US, 5733788 [ P ]. 1998- 03-31.
  • 4O' Neil MJ, Heckelman PE, Koch CB, et al. The Merck Index [ M ]. 14 th ed. Merck Research Laboratories ,2006:0009146.
  • 5Leung N. Treatment of chronic hepatitis B: case selection and duration oftherapy[J]. J Gastroenterol Hepatol, 2002, 17(4): 409-414.
  • 6Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci, 2014, 60(5): 1457-1464. DOl: 10. 1007/s 10620-0 14-3486-7.
  • 7Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis[J]. PLoS One, 2014, 9(6): e98865. DOl: 10.13711journal.pone.0098865.
  • 8Gao L, Trinh HN, Li J, et al. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther, 2014,39(6): 629-637. DOl: 1O.l11l1apt.12629.
  • 9Choi K, Lee HM, Jun BG, et al. Efficacy oftenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B[J]. Korean J Gastroenterol, 2015, 65(1): 35-42.
  • 10Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial[J]. Gut, 2015. DOl: 1O.l136/guYnl-2014-308435.

共引文献38

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部